TIMELINE

In 2015, Single Use Support GmbH founders, Johannes Kirchmair and Thomas Wurm, decided to combine their experiences gained in international technology sales and their specific knowledge concerning single use technology in the biopharma supplier industry with the aim to find solutions for certain pain points that Johannes had encountered during his 15 years in the single use segment of the biopharma industry

„It was no longer tolerable for me that some of the biggest pharmaceutical players on the globe could not solve obvious problems by their own efforts,” says Johannes Kirchmair. „This developed into an ever-growing challenge to find solutions ourselves.“

2015 - 2016

The decision to launch Single Use Support was made and our vision elaborated. We transformed a garage into an office where we researched, developed and manufactured our first prototypes.

2017

Q1

First instance – the single use bag.

Problem to solve:
Integrity – material deficiencies / bio contamination / loss of drug substance

In Q1 2017 we started with the development of MITS, a mobile testing system for single use bags of all standard sizes (up to 50 L) and manufacturers, working on the basis of helium. MITS.2D is mobile, fast and much more precise in its measurement than anything available on the market thus far.

Solved.

Q2

Second instance – single use bag handling & transport.

Problem to solve:
Protection, handling, storage, freeze & thaw suitability, transport

In Q2 2017 RoSS was ready to launch. RoSS is a superior shell system for single use bags of all standard sizes and manufacturers. RoSS is the acronym for Robust Storage and Shipping System. Usability, materials and its modular design found immediate positive response in the industry. However, RoSS is not only a shell; it offers rack compatibility, which was the basis for our vision of the entire process. RoSS shell systems can be stored at a larger number in the RoSS.Ship stainless steel rack container with its active and passive freezing options and GPS tracking functionality.

Solved & New Standard established!

Thomas Wurm

„We founded Single Use Support GmbH because we realized that there is a technological gap in biotech industry. We did not expect that we will grow that fast, but now we see that the industry is hungry for our solutions. Our goal is to form a trusted global player. Customers and regulators confirm that we are on the right way.”

Thomas Wurm / Owner & Founder

Third instance – filling and draining of the single use bag.

Problem to solve:
Duration & sterility, single use and reuse technology touch points

Also in Q2 2017, we introduced a new standard for the simultaneous filling of 20 RoSS units and more with the RoSS.FILL. Apart from ease of handling and the time-saving factor it constitutes a homogenous closed process that equally systemizes filling and draining. In order to keep the process quality at a consistently high level, RoSS.FILL provides statistical data and evidence for each process.

Solved & New Standard established!

Fourth instance – substance freeze & thaw.

Problem to solve:
Duration

Q2 2017 also saw the launch of our freeze-thaw platform, which by now is available in different sizes and performance categories. Our system enables systemic freezing and thawing. In order to keep the process quality at a consistently high level, the Freeze & Thaw Platform provides statistical data and evidence for each process.

Solved & New Standard established!

Thomas Wurm

“Clients told us that they have issues in this process step. (testing, filling, freezing, storage, shipping, thawing and emptying of single use bags with drug substance) We came up with technical solutions. We played ping-pong with some customers to fine tune the ideas, and finally they bought into it.”

Johannes Kirchmair / Owner & Founder

Q3

Fifth instance – the biopharma industry.

Problem to solve:
SUSupport = Super-small startup. Biopharma = Giants. Is there a chance to get together?

Q3 2017 saw a first serious turnover generated with our testing system MITS.2D.
At the same time it became obvious that the first pharmaceutical industry partners recognized the advantages of RoSS. And we can fully agree with the following: It costs a tremendous amount of energy to replace an established process or technology, even if the new technology is superior.

If I had asked people what they wanted, they would have said faster horses. Henry Ford.

Problem Solved.

Thomas Wurm

„A dream is coming true for the medical industry. While we are still busy convincing pharmaceutical giants of our BULK.STREAM and its unbelievable advantages, the EU follows the US in approving the first CAR-T cell therapies. With BULK.STREAM we have not even processed the tip of the iceberg in terms of possible options, and are yet being commissioned to scale down our technology in order to supply the medical industry with a secure logistical basis for this imminent mega-trend.“

Thomas Wurm / Owner & Founder

Q4

Next Step – We need more Space!

Q4 2017 saw us move into our new 800 m2 residence with our first four employees. It comprised an office, an R&D area and sufficient production floor space. We managed to book the first serious major order from a pharmaceutical company and got to work in our new premises.

Thomas Wurm

„We conceived and developed the BULK.STREAM. This process gives biopharmaceutical companies access to a new and almost 100% secure liquid logistics process on the basis of an industry standard, the single use bag.“

Thomas Wurm / Owner & Founder

Conclusion 2017:
Year two. What a year.

From the garage to serious company-building.
What started as a vision was – only one year later – perceived as a technological leader in the biopharma industry.

Wow!

2018

Q1

_

The Q1 2018 started with an extensive funding program, which allowed us to invest in further research and development.
At the same time we received a major order from another player in the biopharma industry – this time for our RoSS shell system.

Q3

_

In Q3 2018, Single Use Support GmbH grew to ten employees.
Furthermore we received the biggest order to date from yet another biopharmaceutical player.

Q4

_

Q4 2018 saw us being awarded with the Tyrolean Innovation Prize. We were also voted second best young entrepreneurs in western Austria, and at the same time we received the biggest order to date from the US. Johannes was invited to introduce the MITS.2D to a panel of 60 international experts at the FDA headquarters in Washington, D.C. – what an accolade!

Thomas Wurm

„While we are growing with our BULK.STREAM and getting our first products for a secure CAR-T logistics process ready for the market, yet another new opportunity is presenting itself. We have received an invitation to establish a new business sector together with a biopharmaceutical player...“

Johannes Kirchmair / Owner & Founder

Conclusion 2018:
Like a movie.

What started with a vision in a garage in 2016 and was developed and made ready for the market in 2017, was gaining ever more traction in 2018. Furthermore, we have been witnessing growing demand regarding CAR-T logistics solutions since mid-2018. The term ‘patient safety’ is given a new meaning.

Single Use Support GmbH nowadays is a:

  • 2,5-year-old organization
  • fast-growing company (organically)
  • technology leader already
  • well-recognized company on the biotech world

2019

Q1

_

Q1 2109 will see the launch of the CGT.STREAM and the first shipment to partners from the biopharma industry.

Q2

_

In Q2 2019 we plan to introduce another liquid STREAM, which is currently being developed.

Our biggest leap since we started:
Innovation requires fresh ideas and the right people with a will to implement those ideas. Organic growth on a high level requires a market like the biopharma market, which is growing at a steady rate and has a requirement for improved standards. It is a development that we believe in and so we are planning to take the biggest leap yet with our young company in 2019!

Read more

Q3

_

In Q3 2019 we aim to push or manufacturing output for BULK.STREAM to the next level, while at the same time massively driving our growth with the CGT.STREAM. More space again: We will expand significantly in terms of production facilities and office space.

Q4

_

In Q4 2019, Singe Use Support will establish three entire liquid STREAM processes and will be able to supply them to customers. Technologically leading. Safe for patients. Due to a growing number of co-operations with partners from the biopharma industry as well as organizations like the FDA we are expecting a multi-dimensional need for our technologies. This will further drive our growth!

Conclusion 2019:
We will move a step closer to a “considerably improved international standard for the biopharma liquid logistics process”.